Media Briefing to Preview the National Immunisation Program for Influenza in 2016
Quadrivalent influenza vaccines to play a key role in
National Immunisation Program for 2016
Media briefing to be convened at 10.30am on Tuesday 22nd March
At Macquarie University Hospital & Clinic, Conference Room (ground floor), 3 Technology Place, North Ryde
A media briefing is being convened to preview the introduction of quadrivalent (four-strain) influenza vaccines on the National Immunisation Program (NIP) for the 2016 influenza (flu) season. An influenza expert and a spokesperson from GlaxoSmithKline (GSK), one of the manufacturers of the quadrivalent influenza vaccines available on the NIP, will be in attendance to provide a preview of the influenza NIP that is expected to begin in April 2016 as stated by the Department of Health1.
This is the first time that quadrivalent influenza vaccines have been used as part of the NIP to reduce the impact of influenza during the peak season. The four-strain flu vaccines are indicated for the prevention of influenza disease caused by two influenza A and two influenza B strains contained in the vaccines2. Four-strain flu vaccines include an additional B strain of influenza virus, compared with three-strain vaccines2.
In 2015 there was a record 100,571 cases3 of laboratory-confirmed influenza in Australia. Influenza B viruses are estimated to have accounted for about 61 per cent of those cases4, 5.
Macquarie University Hospital & Clinic, Conference Room (ground floor), 3 Technology Place, North Ryde, NSW
10.30am to 11.30am on Tuesday 22nd March, 2016.
Who will be there?
Professor Robert Booy, Immunisation and Infectious Disease expert, University of Sydney
Associate Professor Michael Nissen, Director of Scientific Affairs and Public Health, GSK
Enquiries or interview requests please contact: